Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Summary

The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.

Conditions

• Anemia, Cooley's
• Beta-Thalassemia
• Hematologic Diseases
• Thalassemia
• Osteoporosis
• Iron Overload
• Hypertension, Pulmonary

Interventions

DRUG

Deferoxamine

DRUG

Deferiprone

DRUG

Arginine

DRUG

Sildenafil

DRUG

Decitabine

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI)

  collaborator NIH

• Thalassemia Clinical Research Network

  collaborator NETWORK

• Carelon Research

  lead OTHER

Principal Investigators

• Alan R. Cohen, MD · Children's Hospital of Philadelphia

• Patricia J. Giardina, MD · Weill Medical College of Cornell University

• Ellis J. Neufeld, MD, PhD · Children's Hospital Medical Center, Cincinnati

• Nancy F. Olivieri, MD · Toronto General Hospital

• Elliott P. Vichinsky, MD · UCSF Benioff Children's Hospital Oakland

• Sonja McKinlay, PhD · New England Research Institutes, Inc.

Eligibility

Min Age

1 Year

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2000-07-31

Completion

2006-07-31

Countries

• United States
• Canada

Study Locations